Increasing tumor volume is predictive of poor overall and progression-free survival: Secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II …
M Werner-Wasik, RS Swann, J Bradley… - International Journal of …, 2008 - Elsevier
PURPOSE: Patients with non–small-cell lung cancer (NSCLC) in the Radiation Therapy
Oncology Group (RTOG) 93-11 trial received radiation doses of 70.9, 77.4, 83.8, or 90.3 Gy …
Oncology Group (RTOG) 93-11 trial received radiation doses of 70.9, 77.4, 83.8, or 90.3 Gy …